Login

$CVRX SEC Filings

Filed On Filing
12 Nov 2026 Form 4: Landry John, Chief Financial Officer

Received 41,433 shares as a grant or award · Granted 186,447 Stock Option (right to buy)

12 Nov 2026 Form 3: Landry John, Chief Financial Officer

No securities owned

05 Nov 2026 FORM S-8
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

MINNEAPOLIS, November 5, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients wi...

02 Oct 2026 SCHEDULE 13D/A
21 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

On behalf of CVRx, Inc. (“CVRx” or the “Company”), I am pleased to offer you employment with CVRx. Subject to fulfillment of the conditions of employment mentioned in this letter, your estimated hire date will be October 12, 2026, pendin...

24 Aug 2026 SCHEDULE 13D
14 Aug 2026 SCHEDULE 13G
13 Aug 2026 Form 4: Binkowski Brent, CHIEF OPERATING OFFICER

Bought 26,223 shares ($76.4K)

13 Aug 2026 Form 4: Binkowski Brent, CHIEF OPERATING OFFICER

Sold 1,309 shares ($3.34K)

11 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

MINNEAPOLIS, August 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients wit...

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

MINNEAPOLIS, August 6, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with...

09 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

I want to thank you for your service to CVRx, Inc. (the “Company”). I understand you have chosen to transition from CVRx and appreciate your willingness to effect a smooth transition as outlined in this letter agreement (“Agreement”).

03 Jun 2026 Form 4: Nielsen Kirk G., Director

Received 8,720 shares as a grant or award · Granted 11,182 Stock Option (right to buy)

03 Jun 2026 Form 4: Jain Mudit K., Director

Received 8,720 shares as a grant or award · Granted 11,182 Stock Option (right to buy)

03 Jun 2026 Form 4: Slattery Joseph P, Director

Received 8,720 shares as a grant or award · Granted 11,182 Stock Option (right to buy)

03 Jun 2026 Form 4: Hill, Mitch C., Director

Received 8,720 shares as a grant or award · Granted 11,182 Stock Option (right to buy)

03 Jun 2026 Form 4: Ballinger Kevin J., Director

Received 8,720 shares as a grant or award · Granted 11,182 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support